Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01020877 · ClinicalTrials.gov registry record · Phase 1
Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01020877: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT01020877 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01020877, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The primary object of this study was to evaluate the relative bioavailability of the test formulation of metronidazole vaginal gel with the already marketed reference formulation MetroGel-Vaginal Gel® in healthy adult female subjects.
Interventions
- DRUG Metronidazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2001-11 |
| Est. Completion | 2002-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01020877
The ClinicalTrials.gov registry entry for NCT01020877 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metronidazole is the first listed.
NCT01020877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01020877 about?
NCT01020877 is a clinical study titled "Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects". The primary object of this study was to evaluate the relative bioavailability of the test formulation of metronidazole vaginal gel with the already marketed reference formulation MetroGel-Vaginal Gel® in healthy adult female subjects.
What is the current status of trial NCT01020877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2001-11. Estimated completion is 2002-01.
What interventions are being tested in trial NCT01020877?
The interventions under investigation include: Metronidazole (DRUG).
Who is sponsoring clinical trial NCT01020877?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.